Compare iShares MSCI South Africa ETF (EZA) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Africa ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares MSCI South Africa ETF trades at $63.18 (market cap $465.74M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 16.1× iShares MSCI South Africa ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Africa ETF for 73 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EZA | SYRE | |
|---|---|---|
Market Cap | $465.74M | $7.52B |
Volume | 245,187 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $81.60 | $108.92 |
52-Week Low | $60.43 | $22.18 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EZA trades at $64.32, up 0.86% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF, which tracks South African equities, faces headwinds from global reflation and higher capital costs impacting its financial and commodity-heavy holdings. Recent news highlighted a brief move above the 50-day average, but macro concerns dominate the narrative.
The outlook remains cautious due to exposure to volatile sectors like gold and banking amid rising rates. Investment opportunity hinges on South Africa's economic stability, but risks include commodity price pressures and unfavorable yield dynamics. Investor sentiment is neutral to bearish, with technicals suggesting near-term resistance at $64.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
